That EngMab buyout deal by Celgene was a little bigger than we first reported at the end of September.
After hearing that Celgene — one of the most muscular dealmakers in biotech — was telling analysts that it had snagged a deal to buy the Swiss biotech, we confirmed the news with a company spokesman, but only got the upfront for our scoop.
The latest quarterly report from Celgene $CELG reveals that the overall buyout deal is much larger in scope.
